Bristol Myers Squibb Co. (BMY)
66.71
+0.13
(+0.20%)
USD |
NYSE |
Aug 31, 14:32
Bristol Myers Squibb Total Long Term Debt (Quarterly) : 44.59B for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 44.59B |
| March 31, 2026 | 45.91B |
| December 31, 2025 | 46.65B |
| September 30, 2025 | 50.57B |
| June 30, 2025 | 50.50B |
| March 31, 2025 | 50.86B |
| December 31, 2024 | 50.80B |
| September 30, 2024 | 51.03B |
| June 30, 2024 | 53.39B |
| March 31, 2024 | 53.92B |
| December 31, 2023 | 41.06B |
| September 30, 2023 | 38.52B |
| June 30, 2023 | 38.41B |
| March 31, 2023 | 38.70B |
| December 31, 2022 | 40.21B |
| September 30, 2022 | 39.71B |
| June 30, 2022 | 42.57B |
| March 31, 2022 | 45.60B |
| December 31, 2021 | 45.24B |
| September 30, 2021 | 45.38B |
| June 30, 2021 | 45.96B |
| March 31, 2021 | 46.83B |
| December 31, 2020 | 51.17B |
| September 30, 2020 | 45.34B |
| June 30, 2020 | 46.81B |
| Date | Value |
|---|---|
| March 31, 2020 | 46.79B |
| December 31, 2019 | 46.82B |
| September 30, 2019 | 24.89B |
| June 30, 2019 | 24.95B |
| March 31, 2019 | 6.164B |
| December 31, 2018 | 6.895B |
| September 30, 2018 | 6.934B |
| June 30, 2018 | 6.932B |
| March 31, 2018 | 7.02B |
| December 31, 2017 | 6.975B |
| September 30, 2017 | 6.982B |
| June 30, 2017 | 7.661B |
| March 31, 2017 | 7.986B |
| December 31, 2016 | 6.465B |
| September 30, 2016 | 6.585B |
| June 30, 2016 | 6.581B |
| March 31, 2016 | 6.593B |
| December 31, 2015 | 6.55B |
| September 30, 2015 | 6.632B |
| June 30, 2015 | 6.615B |
| March 31, 2015 | 7.127B |
| December 31, 2014 | 7.242B |
| September 30, 2014 | 7.267B |
| June 30, 2014 | 7.372B |
| March 31, 2014 | 7.367B |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Johnson & Johnson | 37.34B |
| Eli Lilly & Co. | 49.62B |
| Merck & Co., Inc. | 51.08B |
| Pfizer Inc. | 63.10B |
| AstraZeneca PLC | 30.91B |